Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94

被引：35

作者：

McSharry, JJ

McDonough, A

Olson, B

Talarico, C

Davis, M

Biron, KK

机构：

[1] Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA

[2] GlaxoSmithKline, Res Triangle Pk, NC USA

来源：

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY | 2001年 / 8卷 / 06期

关键词：

D O I：

10.1128/CDLI.8.6.1279-1281.2001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The average 50% inhibitory concentration (IC50) values for AD169 were 0.22 +/- 0.09 muM 1263W94 and 5.36 +/- 0.12 muM ganciclovir. For 35 human cytomegalovirus (HCMV) clinical isolates the average IC50 was 0.42 +/- 0.09 muM 1263W94, and for 26 ganciclovir-susceptible HCMV clinical isolates the average IC50 was 3.78 +/- 1.62 muM ganciclovir. Nine HCMV clinical isolates: that were resistant to ganciclovir were completely susceptible to 1263W94.

引用

收藏

页码：1279 / 1281

页数：3

相关论文

共 23 条

[1]

BRITT WJ, 1996, FIELDS VIROLOGY, P2493

[2] FREQUENCY OF UL97 PHOSPHOTRANSFERASE MUTATIONS RELATED TO GANCICLOVIR RESISTANCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES [J].

CHOU, SW ;

GUENTZEL, S ;

MICHELS, KR ;

MINER, RC ;

DREW, WL .

JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (01) :239-242

[3] ANALYSIS OF THE UL97 PHOSPHOTRANSFERASE CODING SEQUENCE IN CLINICAL CYTOMEGALOVIRUS ISOLATES AND IDENTIFICATION OF MUTATIONS CONFERRING GANCICLOVIR RESISTANCE [J].

CHOU, SW ;

ERICE, A ;

JORDAN, MC ;

VERCELLOTTI, GM ;

MICHELS, KR ;

TALARICO, CL ;

STANAT, SC ;

BIRON, KK .

JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :576-583

[4]

Chulay J, 1999, ADV EXP MED BIOL, V458, P129

[5] Drug therapy - Ganciclovir [J].

Crumpacker, CS .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) :721-729

[6] Resistance of human cytomegalovirus to antiviral drugs [J].

Erice, A .

CLINICAL MICROBIOLOGY REVIEWS, 1999, 12 (02) :286-+

[7] Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients [J].

Erice, A ;

GilRoda, C ;

Perez, JL ;

Balfour, HH ;

Sannerud, KJ ;

Hanson, MN ;

Boivin, G ;

Chou, SW .

JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) :1087-1092

[8] Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis [J].

Jabs, DA ;

Enger, C ;

Forman, M ;

Dunn, JP .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2240-2244

[9] Cytomegalovirus retinitis and viral resistance: Ganciclovir resistance [J].

Jabs, DA ;

Enger, C ;

Dunn, JP ;

Forman, M .

JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (03) :770-773

[10] Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56 [J].

Krosky, PM ;

Underwood, MR ;

Turk, SR ;

Feng, KWH ;

Jain, RK ;

Ptak, RG ;

Westerman, AC ;

Biron, KK ;

Townsend, LB ;

Drach, JC .

JOURNAL OF VIROLOGY, 1998, 72 (06) :4721-4728